Fundraising FoxFrazier Life Sciences — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.
BiotechDeep TechHealthtechSouth San Francisco, US
Cameron Pitt(Executive Officer, Director)inDerek Metzger(Executive Officer)
BoardMaha Katabi(Director)inPerry Nisen(Executive Officer, Director)inRajul Jain(Director)in
Board seatMaria Fardis· per SEC Form D · $89.1M raise · filed Jun 2026
Co-investorsFinchley Healthcare VenturesLongitude CapitalSofinnova VenturesVida VenturesBiotechnology Value Fund
BiotechMenlo Park, US
Brett Ewald(Executive Officer)inUmesh Gangadharmath(Executive Officer)inIstvan Molnar(Executive Officer)inYunfei Zhu(Executive Officer)Ana Kusnetzow(Executive Officer)inScott Struthers(Director)
Co-investorsDCVC (Data Collective)5AM VenturesDCVC BioFrazier Healthcare PartnersWestlake Village BioPartners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.